[CAS NO. 74389-68-7] C16-PAF
PRODUCTS SPECIFICATIONS [74389-68-7]
DESCRIPTION [74389-68-7]
Overview
| MDL | MFCD00043214 |
|---|---|
| Molecular Weight | 523.68 |
| Molecular Formula | C26H54NO7P |
| SMILES | CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP(OCC[N+](C)(C)C)([O-])=O |
4 Publications Citing Use of MCE
Summary
C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor ( PAFR ). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and MEK/ERK activator. C16-PAF induces increased vascular permeability [1] [2] [3] [4] [5] .
IC50 & Target
|
Human Endogenous Metabolite |
ERK |
MEK |
In Vitro
C16-PAF (PAF (C16); 0.5-1.5 μM; for 24 hours) elicits significant concentration-dependent neuronal loss in PAFR
−/−
but not PAFR
+/+
cultures. C16-PAF (1 μM) elicits neuronal death in PAFR
−/−
cells infected with EGFP alone
[1]
.
C16-PAF (1 μM; for 24 hours) activates caspase 7 but not caspase 3 in PAFR
−/−
neurons
[1]
.
C16-PAF is synthesized by two distinct pathways; the remodeling pathway and the de novo synthesis pathway. C16-PAF acts by binding to a unique G-protein-coupled seven transmembrane receptor
[2]
[3]
.
C16-PAF (1-25 μg/ml; 6, 12, 24 h) inhibits
M. smegmatis
and
M. bovis
BCG growth in a time-dependent manner
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | Cerebellar granule neurons (CGNs) from PAFR −/− and PAFR +/+ mice |
| Concentration: | 0.5-1.5 μM |
| Incubation Time: | 24 hours |
| Result: | Elicited significant concentration-dependent neuronal loss in PAFR −/− but not PAFR +/+ cultures in serum-free media. |
Western Blot Analysis [1]
| Cell Line: | CGNs |
| Concentration: | 1 μM |
| Incubation Time: | 24 hours |
| Result: | Activated caspase 7 but not caspase 3 in PAFR −/− neurons. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Solvent & Solubility
DMSO : 50 mg/mL ( 95.48 mM ; Need ultrasonic)
H 2 O : 33.33 mg/mL ( 63.65 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.9096 mL | 9.5478 mL | 19.0956 mL |
| 5 mM | 0.3819 mL | 1.9096 mL | 3.8191 mL |
| 10 mM | 0.1910 mL | 0.9548 mL | 1.9096 mL |
References
- [1] Scott D Ryan, et al. Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons. J Lipid Res. 2008 Oct;49(10):2250-8.
- [2] Z Honda, et al. Transfected platelet-activating factor receptor activates mitogen-activated protein (MAP) kinase and MAP kinase kinase in Chinese hamster ovary cells. J Biol Chem. 1994 Jan 21;269(3):2307-15.
- [3] Muhammad S Riaz, et al. Direct Growth Inhibitory Effect of Platelet Activating Factor C-16 and Its Structural Analogs on Mycobacteria. Front Microbiol. 2018 Sep 11;9:1903.
- [4] Jing Chu, et al. IGHG1 Regulates Prostate Cancer Growth via the MEK/ERK/c-Myc Pathway. Biomed Res Int. 2019 Jul 4;2019:7201562.
- [5] Nina Bögershausen, et al. RAP1-mediated MEK/ERK pathway defects in Kabuki syndrome. J Clin Invest. 2015 Sep;125(9):3585-99.
Synonyms
